Q: What therapeutic areas does Tianjin Medical University Second Hospital research focus on?

Tianjin Medical University Second Hospital clinical trials span Solid Tumor, Adult, Next-generation Sequencing, Precision Medicine, Urothelial Carcinoma (UC), Bladder (Urothelial, Transitional Cell) Cancer, and additional conditions. The research pipeline includes Phase 1, Phase 2, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

Question 1

How many clinical trials has Tianjin Medical University Second Hospital sponsored?

Accepted Answer

ClinicalMetric currently tracks 6 clinical trials sponsored by Tianjin Medical University Second Hospital, of which 6 are actively recruiting participants. These trials cover conditions including Solid Tumor, Adult, Next-generation Sequencing, Precision Medicine. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

Question 2

What therapeutic areas does Tianjin Medical University Second Hospital research focus on?

Accepted Answer

Tianjin Medical University Second Hospital is a clinical research sponsor with 6 registered studies on ClinicalTrials.gov, of which 6 are actively recruiting participants. Research covers conditions including Solid Tumor, Adult, Next-generation Sequencing, Precision Medicine, Urothelial Carcinoma (UC).

The trial portfolio spans Phase 1, Phase 2, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Question 3

How do I participate in a Tianjin Medical University Second Hospital clinical trial?

Accepted Answer

To participate in a Tianjin Medical University Second Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Tianjin Medical University Second Hospital trials with current recruitment status updated daily.

Tianjin Medical University Second Hospital

Frequently Asked Questions — Tianjin Medical University Second Hospital

Clinical Trials by Tianjin Medical University Second Hospital

Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma

Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer

Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer

Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors